Crinetics Pharmaceuticals (CRNX) said late Thursday the first patient has been dosed in the phase 2/3 trial of atumelnant in Congenital Adrenal Hyperplasia.
The study in children and adolescents will be carried out in three phases, the company said.
Crinetics Pharmaceuticals (CRNX) said late Thursday the first patient has been dosed in the phase 2/3 trial of atumelnant in Congenital Adrenal Hyperplasia.
The study in children and adolescents will be carried out in three phases, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.